Definium Therapeutics scores below the minimum quality threshold on all profitability metrics, has missed earnings estimates in each of the last four quarters with an average shortfall of 35%, and concentrates its entire pipeline on a single clinical program supplied by a single contract manufacturer — while the technical setup has turned constructive following a golden cross, the fundamental execution risks are severe enough that the setup warrants avoiding new exposure.
Thesis pillars
- Single Program Supplier Concentration↓Deteriorating
- Quality Below Minimum Floor→Stable
- Persistent Earnings Miss Streak↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Definium Therapeutics, Inc. (DFTX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $32.70: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.48; Below-average business quality; Negative price momentum.
Definium Therapeutics is a clinical-stage biopharmaceutical company with no approved products, advancing DT120 ODT (lysergide tartrate) through Phase 3 trials for generalized anxiety disorder and major depressive disorder, and DT402 (R(-)-MDMA) through Phase 2a for autism... Read more
Sell if holding. Engine safety override at $32.70: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.48; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 4d<=7d. Suitability: speculative.
About Definium Therapeutics, Inc.
About Definium Therapeutics, Inc.
Definium Therapeutics reported a net loss of $183.8 million for the year ended December 31, 2025 and held $411.6 million in cash, cash equivalents, and investments—sufficient, by the company's estimate, to fund operations into 2028. DT120 ODT, a lysergide tartrate formulation granted FDA breakthrough designation for generalized anxiety disorder in March 2024, is in two Phase 3 GAD trials (Voyage and Panorama) with topline readouts expected in early Q3 2026 and the second half of 2026, respectively. A Phase 3 MDD trial, Emerge (149 participants), targets a late Q2 2026 topline readout.
Definium generates no product revenue; operations have been funded through equity offerings and a loan facility with K2 HealthVentures LLC under which the company borrowed $42.0 million in April 2025. Drug supply for all clinical studies is sourced from multiple contract development and manufacturing organizations on a purchase-order basis—the company holds no manufacturing facilities. The Zydis ODT formulation technology used in DT120 is covered by an exclusive licensing agreement with Catalent, granting rights in the United States, United Kingdom, and European Union, among other key jurisdictions. A second MDD Phase 3 study, Ascend, activated initial sites in Q1 2026 with first patient dosing targeted by early Q2 2026; DT402, an R-enantiomer of MDMA for autism spectrum disorder, completed Phase 1 in October 2024 and entered Phase 2a in Q4 2025. An accumulated deficit of $582.7 million as of December 31, 2025 reflects the costs of clinical development since the company commenced operations in 2019.
Show full overview
The company's entire clinical-stage pipeline is dependent on the outcome of DT120 Phase 3 readouts. The Voyage study (200 participants) completed its blinded interim sample-size re-estimation with no increase required; Panorama (250 participants) uses an adaptive design allowing up to 50% sample-size expansion. The 10-K discloses that failure to achieve regulatory approval for DT120 would require additional capital, and if adequate funds are unavailable on acceptable terms, the company could be forced to delay or eliminate development programs. DT402 remains in early Phase 2a with up to 20 participants, offering no near-term regulatory milestone as a fallback.
See also: Healthcare · Biotechnology
From Definium Therapeutics, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Definium Therapeutics, Inc.
Latest news
- NEWS Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT at 2026 NEI Fall Congress — fiscal.ai Nov 4, 2026 positive
- NEWS Definium Therapeutics To Present Phase 3 Panorama Data Of LSD-Based DT120 In Generalized Anxiety Disorder, Pooled Phase — benzinga Nov 4, 2026 positive
- NEWS Definium Therapeutics Announces Participation in Upcoming Investor Conferences — fiscal.ai Nov 3, 2026 neutral
- NEWS 'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana — benzinga Oct 29, 2026 neutral
- NEWS RBC Analyst Commentary on Definium Therapeutics' Commercial Scalability — fiscal.ai Oct 19, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:54:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineDT120 ODT10-K Item 1A: 'Our most advanced development candidate is DT120 ODT ... Phase 3 clinical program in GAD in December 2024 ... Phase 3 clinical program in MDD in April 2025'
- HIGHSupplierCatalent10-K Item 1: 'exclusive licensing agreement with Catalent for its patented Zydis® ODT technology ... Catalent has granted us access to its Zydis technology for the development of DT120 ODT'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $32.70: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.48; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $30.66. Score 5.2/10, moderate confidence.
Analyst target: $65.30 (+99.7% upside). Prior stop was $30.66. Stop-loss: $30.66.
Concentration risk — Pipeline: DT120 ODT; Concentration risk — Supplier: Catalent; Quality below floor (1.9 < 4.0).
Definium Therapeutics, Inc. trades at a P/E of N/A (forward -16.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts rate DFTX, with a consensus score of 4.3/5. 18 analysts publish price targets averaging $73.
What does Definium Therapeutics, Inc. do?Definium Therapeutics is a clinical-stage biopharmaceutical company with no approved products, advancing DT120 ODT...
Definium Therapeutics is a clinical-stage biopharmaceutical company with no approved products, advancing DT120 ODT (lysergide tartrate) through Phase 3 trials for generalized anxiety disorder and major depressive disorder, and DT402 (R(-)-MDMA) through Phase 2a for autism spectrum disorder. The FDA granted breakthrough designation to the DT120 GAD program in March 2024; the company held $411.6 million in cash as of December 31, 2025, with runway into 2028.